{
    "root": "74c3457e-079c-4b2b-bae4-3f148540a27a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Pramipexole dihydrochloride",
    "value": "20250424",
    "ingredients": [
        {
            "name": "PRAMIPEXOLE DIHYDROCHLORIDE",
            "code": "3D867NP06J"
        },
        {
            "name": "HYPROMELLOSE 2208 (15000 MPA.S)",
            "code": "Z78RG6M2N2"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "SODIUM METABISULFITE",
            "code": "4VON5FNS3C"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        }
    ],
    "indications": "Pramipexole dihydrochloride extended- release tablet is a non-ergot dopamine agonist indicated for the treatment of Parkinson's disease (PD) ( 1 )",
    "contraindications": "Pramipexole dihydrochloride extended- release tablets are taken once daily, with or without food ( 2.1 ) Tablets must be swallowed whole and must not be chewed, crushed, or divided ( 2.1 ) Starting dose is 0.375 mg given once daily ( 2.2 ) Dose may be increased gradually, not more frequently than every 5 to 7 days, first to 0.75 mg per day and then by 0.75 mg increments up to a maximum recommended dose of 4.5 mg per day. Assess therapeutic response and tolerability at a minimal interval of 5 days or longer after each dose increment ( 2.2 ) Patients may be switched overnight from immediate-release pramipexole tablets to pramipexole dihydrochloride extended- release tablets at the same daily dose. Dose adjustment may be needed in some patients ( 2.3 ) Pramipexole dihydrochloride extended- release tablets should be discontinued gradually ( 2.2 )",
    "warningsAndPrecautions": "Pramipexole dihydrochloride extended- release tablets are available as follows:\n                        0.375 mg: white or off-white, round, biconvex tablets debossed \"0.375\" on one side and \"P11\" on the other side.\n                        Unit of Use Bottles of 30                        NDC 50742-331-30\n                        0.75 mg: white or off-white, round, biconvex tablets debossed \"0.75\" on one side and \"P12\" on the other side.\n                        Unit of Use Bottles of 30                        NDC 50742-332-30\n                        1.5 mg: white or off-white, oval, biconvex tablets debossed \"1.5\" on one side and \"P13\" on the other side.\n                        Unit of Use Bottles of 30                        NDC 50742-333-30\n                        2.25 mg: white or off-white, oval, biconvex tablets debossed \"2.25\" on one side and \"P14\" on the other side.\n                        Unit of Use Bottles of 30                        NDC 50742-334-30\n                        3 mg: white or off-white, oval, biconvex tablets debossed \"3.0\" on one side and \"P15\" on the other side.\n                        Unit of Use Bottles of 30                        NDC 50742-335-30\n                        3.75 mg: white or off-white, oval, biconvex tablets debossed \"3.75\" on one side and \"P16\" on the other side.\n                        Unit of Use Bottles of 30                        NDC 50742-336-30\n                        4.5 mg: white or off-white, oval, biconvex tablets debossed \"4.5\" on one side and \"P17\" on the other side.\n                        Unit of Use Bottles of 30                        NDC 50742-337-30",
    "adverseReactions": "None."
}